157187-06-9

Upstream product

• 6342-70-7 3-methoxymethylsalicylate 
• 877-22-5 3-methoxysalicylic acid 
• 157187-05-8 2-dimethylthiocarbamoyloxy-3-methoxybenzoic acid methyl ester 

Downstream Products

• 215648-27-4 2-mercapto-3-methoxybenzoic acid methyl ester 
• 83596-91-2 3-methoxy-2-mercaptobenzoic acid 
• 157187-08-1 2-Carbomethoxy-6-methoxybenzenesulfonic acid dimethylamine salt 
• 215648-56-9 2-chlorosulfonyl-3-methoxybenzoic acid methyl ester 
• 944061-03-4 3-hydroxy-7-methoxy-1-benzothiophene-2-carbonitrile 
• 944060-99-5 methyl 2-[(cyanomethyl)thio]-3-methoxybenzoate 

Relevant academic research and scientific papers

Synthesis and structure activity relationship studies of benzothieno[3,2-b]furan derivatives as a novel class of IKKβ inhibitors

As a novel class of IKKβ inhibitors, a series of tricyclic furan derivatives was designed and synthesized based on the structure of known thiophene IKKβ inhibitors. Among the various fused furan derivatives synthesized, a benzothieno[3,2-b]furan derivative 13a displayed potent inhibitory activity towards IKKβ in enzymatic and cellular assays. The potent inhibitory activity originates from an intramolecular non-bonded S...O interaction which was confirmed by the X-ray structure of JNK3 with 16k. The introduction of further substituents on the core structure led to the discovery of the 6-alkoxy derivatives, which possessed a comparable IKKβ inhibitory activity to 13a and an improved metabolic stability. Among these, appropriately lipophilic compounds 16a, h, i, and 13g (logD>2) were found to possess good oral bioavailability.

Endothelin receptor antagonists: Synthesis and structure-activity relationships of substituted benzothiazine-1,1-dioxides

The development of benzothiazine-1,1-dioxide derivatives as a new structural class of potent endothelin receptor antagonists is described. Structure-activity relationships (SAR) revealed that PD164800 (1) is a potent antagonist of the ET(A) receptor subtype. Copyright (C) 1998 Elsevier Science Ltd.

Angiotensin II antagonists

This invention provides novel heterocyclic derivatives, their pharmaceutical formulations, and their use for antagonizing angiotensin II receptors in mammals.

Angiotensin II antagonist intermediates

This invention provides novel heterocyclic derivatives, their pharmaceutical formulations, and their use for antagonizing angiotensin II receptors in mammals.

Angiotensin II antagonists

This invention provides novel phenyl and heterocyclic derivatives, their pharmaceutical formulations and their methods of use for antagonizing angiotensin II receptors in mammals.